Berberine, an isoquinoline alkaloid isolated from plants such as Berberis aristata, has been extensively studied for its broad-spectrum pharmacological activities, including anti-diabetic, antiinflammatory, lipid-lowering, and antimicrobial effects. Despite its promising therapeutic potential, the clinical translation of berberine has been largely constrained by its poor oral bioavailability.
To overcome these limitations, we have developed Liposomal Berberine using our proprietary LIPOZOID™ technology, ensuring superior stability, absorption, and efficacy.
True Liposomal Structure with Enhanced Stability
Our Liposomal berberine is formulated using LIPOZOID™, an advanced liposomal encapsulation technology that provides:
True Liposomal Structure – Unlike conventional emulsions or micelles, our formulation ensures that Berberine is encapsulated within bilayer lipid vesicles, mimicking the natural phospholipid membrane of cells. This structure enhances its cellular uptake and prevents premature
degradation.
Good Zeta Potential Stability (-62.8 mV) – The zeta potential of our liposomes ensures electrostatic repulsion, preventing aggregation and enhancing stability in suspension. This results in a longer shelf life and better dispersibility in physiological conditions.
Optimized Particle Size (below 250 nm) – Our liposomes are engineered to have an average particle size of 70.4 nm, ensuring efficient cellular uptake while maintaining stability during storage and transport.
